Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	DC	20549
vvasilington,	D.O.	20070

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Khosla Rachna						2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]									k all app Direc	licable)	ng Person(s) to I		
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 04/27/2022									X	belov	v) ``	below)		
(Street) THOUS OAKS	AND CA	A 9	1320		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Individual or Joint/Group Filing (Check Applic Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					son
(City)	(St	ate) (Ž	Zip)												1 0100	511			
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired	l, Dis	posed of	, or E	Benefic	ially	<b>Own</b>	ed			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)						Execution Date,		ate,				Acquired (A) or f (D) (Instr. 3, 4 and			Beneficially Owned Followir		6. Ownershi Form: Direc (D) or Indire (I) (Instr. 4)		of Indirect Beneficial Ownership
									Code	v	Amount	(A) o	Price		Transa	Reported Fransaction(s) Instr. 3 and 4)			(Instr. 4)
Common Stock 04/27/2				022			F		28	D	\$249	9.87 6,828		328(1)(2)	D				
		Tal	ble II -								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code ( 8)	ransaction of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amoun or Numbe of Title Shares		nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

## **Explanation of Responses:**

1. These shares include the following RSUs granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 280 RSUs which vest in installments of 138 on 5/3/2022 and 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

/s/ Rachna Khosla

04/29/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.